More patients are accessing a growing number of newly-approved cell and gene therapies, plus transplants and other complex and high-cost specialty treatments – many for unfamiliar conditions not previously treatable. Emerging Therapy Solutions® (ETS) offers providers a simplified contracting process and program promotion by leveraging its relationships with national payers, jumbo employers, and other risk-bearing entities.
By the end of 2026, ETS estimates that there will be over 50 complex or rare indications* for which new cell and gene therapies will be available. With therapy biologic costs ranging from $338k to $4.25 million, and administration costs ranging from $300k to $800k, individual treatment claim costs will increase exponentially leading to greater expense, outlay, and risk for you.
Emerging Therapy Solutions was founded because of this growth in treating rare and complex medical conditions. We help our clients manage the immense risk, costs and intricate processes associated with these treatments.
As a recognized leader in cell and gene therapy, and stem cell and solid organ transplant services, ETS focuses on providing expert clinical content, payer education, and access to negotiated, contracted rates at qualified centers.
We do the heavy lifting by minimizing administrative burden through:
We educate payers and employers, about cell and gene therapies and the associated conditions with:
ETS is uniquely positioned to facilitate access to cell and gene therapies and other complex care.
ETS fosters connection by promoting programs and providers to payer clients, including:
Provider Program Awareness, Nationwide Reach & Simplicity
By partnering with ETS, work with a business that offers: